Skip to main content

Surrozen, Inc. (SRZN)

NASDAQ: SRZN · IEX Real-Time Price · USD
9.02
-0.28 (-3.01%)
At close: Nov 26, 2021 1:00 PM
9.01
-0.01 (-0.11%)
After-hours:Nov 26, 2021 1:00 PM EST

Company Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.

It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts.

The company was founded in 2016 and is headquartered in South San Francisco, California.

Surrozen, Inc.
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees2,021

Contact Details

Address:
171 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone650 489 9000
Websitesurrozen.com

Stock Details

Ticker SymbolSRZN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1824893

Key Executives

NamePosition
Craig C. Parker M.B.A.Chief Executive Officer, President and Director
Charles WilliamsChief Financial Officer
Dr. Wen-Chen Yeh M.D., Ph.D.Chief Scientific Officer
Dr. K. Christopher GarciaCo-Founder and Member of Scientific Advisor
Dr. Roeland Nusse Ph.D.Co-Founder and Member of Scientific Advisor
Dr. Calvin KuoCo-Founder and Member of Scientific Advisor
Dr. Johannes Carolus Clevers M.D., Ph.D.Co-Founder and Member of Scientific Advisor
Sheela Mohan-PetersonVice President of Legal
Reza Afkhami M.B.A.Vice President of Corporate Development and Strategy
Elizabeth NguyenHead of Human Resources and Vice President

Latest SEC Filings

DateTypeTitle
Nov 16, 2021424B3Prospectus [Rule 424(b)(3)]
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 15, 20218-KCurrent report
Nov 9, 2021424B3Prospectus [Rule 424(b)(3)]
Nov 10, 2021EFFECTNotice of Effectiveness
Nov 8, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Nov 8, 2021S-8Securities to be offered to employees in employee benefit plans
Sep 29, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Sep 13, 2021S-1General form for registration of securities under the Securities Act of 1933
Aug 23, 2021SC 13DGeneral statement of acquisition of beneficial ownership
View All SEC Filings